Boston starts drug-eluting stent trial enrolment:
This article was originally published in Clinica
Boston Scientific (Massachusetts, US) has begun the enrolment phase of its 532-patient, international study to assess its drug-eluting stent. The TAXUS II trial, which is being led by cardiologist Antonio Colombo, of EMO Centro Cuore Colombus, Milan, Italy, will investigate the use of Boston's paclitaxel-eluting stent technology as a means of preventing restenosis. Data from the trial will be used to support an application to market the product in Europe and in other international markets, the firm says.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.